What I found interesting is a subset of bio-twitter finding the FGEN CRL appropriate and/or expected which also thought AKBA had a reasonable chance at approval.
No matter what your feelings on the FGEN data set and the 'cleanliness' thereof - AKBA stood no chance.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.